| Palm Garden Of Clearwater | |
| 3480 Mcmullen Booth Rd, Clearwater, Florida 33761 | |
| (727) 786-6697 | |
| Name | Palm Garden Of Clearwater |
|---|---|
| Location | 3480 Mcmullen Booth Rd, Clearwater, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 117 |
| Occupancy Rate | 120.43% |
| Medicare ID (CCN) | 105581 |
| Legal Business Name | Palm Garden Of Clearwater Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1457786410 |
| Organization Name | PALM GARDEN OF CLEARWATER LLC |
| Doing Business As | PALM GARDEN OF CLEARWATER |
| Address | 3480 N Mcmullen Booth Rd, Clearwater, FL 33761 |
| Phone Number | 727-786-6697 |
News Archive
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.
Hip fractures are a common cause of morbidity and mortality in elderly patients. Cervical myelopathy is a common neurological condition that can diminish balance and coordination. In new research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), investigators screened 28 hip fracture patients and 35 hip replacement patients for cervical myelopathy. Eighteen percent (five) of the hip fracture patients did indeed have cervical myelopathy. None of the hip replacement patients tested positive for the condition.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
› Verified 5 days ago
| NPI Number | 1750387965 |
| Organization Name | SA-PG-CLEARWATER LLC |
| Doing Business As | PALM GARDEN OF CLEARWATER |
| Address | 3480 N Mcmullen Booth Rd, Clearwater, FL 33761 |
| Phone Number | 727-786-6697 |
News Archive
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.
Hip fractures are a common cause of morbidity and mortality in elderly patients. Cervical myelopathy is a common neurological condition that can diminish balance and coordination. In new research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), investigators screened 28 hip fracture patients and 35 hip replacement patients for cervical myelopathy. Eighteen percent (five) of the hip fracture patients did indeed have cervical myelopathy. None of the hip replacement patients tested positive for the condition.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.
Hip fractures are a common cause of morbidity and mortality in elderly patients. Cervical myelopathy is a common neurological condition that can diminish balance and coordination. In new research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), investigators screened 28 hip fracture patients and 35 hip replacement patients for cervical myelopathy. Eighteen percent (five) of the hip fracture patients did indeed have cervical myelopathy. None of the hip replacement patients tested positive for the condition.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.83 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.32 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 52.11 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.36 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.31 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.52 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.25 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.26 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.86 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.09 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.72 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.93 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.15 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.59 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 85.06 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 93.07 | 82.93 |
News Archive
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.
Hip fractures are a common cause of morbidity and mortality in elderly patients. Cervical myelopathy is a common neurological condition that can diminish balance and coordination. In new research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), investigators screened 28 hip fracture patients and 35 hip replacement patients for cervical myelopathy. Eighteen percent (five) of the hip fracture patients did indeed have cervical myelopathy. None of the hip replacement patients tested positive for the condition.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
› Verified 5 days ago
Orchid Cove At Clearwater Location: 1980 Sunset Point Rd, Clearwater, Florida 33765 Phone: (727) 443-1588 | |
Kensington Gardens Rehab And Nursing Center Location: 2055 Palmetto St, Clearwater, Florida 33758 Phone: (727) 461-6613 | |
Palm Garden Of Clearwater Location: 3480 Mcmullen Booth Rd, Clearwater, Florida 33761 Phone: (727) 786-6697 |